What it's for (Indications)
- Etifoxine is primarily indicated for the symptomatic treatment of anxiety disorders and related psychosomatic manifestations.
- It is utilized in clinical settings where a non-benzodiazepine anxiolytic is deemed appropriate, particularly for patients experiencing anxious tension, somatization of anxiety, or psychological distress.
- Its therapeutic effects are attributed to its anxiolytic properties, which help to alleviate the subjective feelings of anxiety, restlessness, and associated physical symptoms.
- The drug is considered for short-term management, aiming to provide relief from acute anxiety states or exacerbations of chronic anxiety, often as an adjunct to non-pharmacological interventions such as psychotherapy.
- This medication is not intended for the treatment of major depressive disorder or other primary psychiatric conditions where anxiety is merely a secondary symptom.
- The decision to prescribe etifoxine should be based on a comprehensive assessment of the patient's anxiety severity and overall clinical presentation, ensuring its use aligns with established treatment guidelines for anxiety management.
- Its use in specific populations, such as the elderly, requires careful consideration due to potential differences in pharmacokinetics and increased sensitivity to adverse effects.
- The therapeutic benefit is typically observed within a short period of initiation, offering relief from distressing symptoms.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical adult dosage of etifoxine (e.g., Stresam) for the treatment of anxiety disorders is generally 50 mg administered two to three times daily, or 100 mg taken twice daily, depending on the severity of symptoms and individual patient response. The capsules are to be swallowed whole with water, without chewing, and preferably taken during meals to minimize potential gastrointestinal discomfort. The duration of treatment should be as short as possible, generally not exceeding a few weeks, to mitigate potential risks and prevent the development of dependence, although the risk is considered lower than with classical benzodiazepines. Dosage adjustments may be necessary for patients with mild to moderate renal or hepatic impairment, requiring careful titration and monitoring. For elderly patients, a reduced starting dose and slower titration are often recommended due to increased sensitivity to central nervous system depressant effects and altered drug metabolism. Abrupt discontinuation of etifoxine, especially after prolonged use, is not generally recommended; a gradual tapering of the dose is advisable to prevent potential withdrawal symptoms or rebound anxiety. Adherence to prescribed dosages and consultation with a healthcare professional before altering treatment regimens are crucial for optimal therapeutic outcomes and patient safety. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with etifoxine therapy are generally mild and transient.
- These include somnolence (drowsiness), particularly at the initiation of treatment, and lightheadedness.
- While these effects are typically less pronounced than those observed with benzodiazepines, patients should be cautioned about operating machinery or driving until they know how the medication affects them.
- Gastrointestinal disturbances such as nausea, abdominal discomfort, and diarrhea may also occur.
- Allergic reactions, including skin rashes, urticaria (hives), and angioedema, have been reported and necessitate immediate medical attention.
- More serious, albeit rare, adverse reactions include severe cutaneous adverse reactions (SCARs) such as Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN).
- These severe skin reactions can be life-threatening and require immediate discontinuation of the drug and emergency medical intervention.
- Cases of hepatic injury, including hepatitis and elevated liver enzymes, have also been reported, necessitating monitoring of liver function tests in patients presenting with symptoms suggestive of liver dysfunction.
- Any unusual or severe symptoms should be promptly reported to a healthcare provider.
Serious Warnings
- Black Box Warning: **Serious Warnings Regarding Severe Adverse Reactions** While etifoxine does not carry an FDA-mandated Black Box Warning as it is not approved for use in the United States, clinicians and patients must be made aware of several serious and potentially life-threatening adverse reactions reported with its use in regions where it is prescribed. Foremost among these are severe cutaneous adverse reactions (SCARs), including Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN). These reactions can manifest rapidly and require immediate medical attention, including prompt and permanent discontinuation of etifoxine. Patients should be vigilantly monitored for new or worsening dermatological manifestations, and advised to seek urgent medical care if they develop skin rashes, fever, lymphadenopathy, or facial swelling. Furthermore, cases of severe hepatic injury, including fulminant hepatitis and liver failure, some with fatal outcomes, have been reported with etifoxine. Liver function should be assessed prior to treatment and monitored if clinically indicated or if symptoms suggestive of liver dysfunction appear (e.g., unexplained persistent nausea, vomiting, abdominal pain, jaundice, dark urine, or pruritus). The drug must be discontinued immediately if significant hepatic abnormalities are detected or suspected. Although the risk of dependence is considered lower than with conventional benzodiazepines, physical and psychological dependence can occur, particularly with prolonged use or at higher doses. Abrupt discontinuation after extended therapy may precipitate withdrawal symptoms or rebound anxiety. Patients should be monitored for signs of dependence and withdrawal, and a gradual dosage tapering is recommended for discontinuation. Additionally, etifoxine may potentiate the effects of central nervous system depressants, including alcohol, increasing the risk of profound sedation, respiratory depression, and impaired psychomotor function. Patients should be strictly cautioned against concomitant use with other CNS depressants or alcohol. These serious warnings underscore the critical importance of careful patient selection, ongoing clinical monitoring, and comprehensive patient education regarding the potential for severe adverse outcomes during etifoxine therapy.
- Etifoxine should be used with caution in patients with a history of hepatic or renal impairment, as its metabolism and excretion may be altered, potentially leading to increased plasma concentrations and an enhanced risk of adverse effects.
- Regular monitoring of liver and kidney function may be warranted in these populations.
- Concomitant use of etifoxine with alcohol or other central nervous system (CNS) depressants, including other anxiolytics, sedatives, hypnotics, opioid analgesics, and antihistamines, should be avoided or approached with extreme caution, as it can potentiate the sedative effects and increase the risk of respiratory depression and profound sedation.
- Patients should be advised against consuming alcohol during treatment.
- Although the risk of dependence and withdrawal is considered lower than with benzodiazepines, prolonged use, especially at higher doses, may lead to physical or psychological dependence.
- Abrupt discontinuation after extended therapy should be avoided, and a gradual dosage tapering regimen is recommended to minimize potential withdrawal symptoms or rebound anxiety.
- Patients should be monitored for signs of dependence.
- Etifoxine is not recommended for use in children and adolescents due to insufficient data on safety and efficacy in this age group.
- Careful consideration should be given to elderly patients who may be more susceptible to CNS depressant effects and other adverse reactions, necessitating lower starting doses and close monitoring.
How it Works (Mechanism of Action)
Etifoxine exerts its anxiolytic effects primarily through its unique modulation of the gamma-aminobutyric acid type A (GABA-A) receptor complex, distinct from the binding site of benzodiazepines. It acts as a non-benzodiazepine anxiolytic by allosterically modulating the GABA-A receptor, enhancing the inhibitory effects of GABA. Specifically, etifoxine has been shown to bind to a novel site on the GABA-A receptor, potentially involving the β2 and β3 subunits, leading to an increase in the frequency of chloride channel opening. This augmentation of GABAergic neurotransmission results in a hyperpolarization of neurons, thereby reducing neuronal excitability and producing anxiolytic and mild sedative effects. In addition to its direct interaction with GABA-A receptors, etifoxine also stimulates the biosynthesis of neurosteroids, such as allopregnanolone and tetrahydrodeoxycorticosterone (THDOC), in the brain and peripheral nervous system. These neurosteroids are potent positive allosteric modulators of GABA-A receptors, acting at a different site than benzodiazepines and increasing the duration of chloride channel opening. This dual mechanism – direct GABA-A receptor modulation and indirect enhancement via neurosteroid synthesis – contributes to its anxiolytic properties without significant impact on memory or motor function at therapeutic doses, differentiating it from traditional benzodiazepines.
Commercial Brands (Alternatives)
No other brands found for this formula.